BioSpace News Archive

Research seems to concur that a person who has recovered from severe COVID-19 symptoms might experience cognitive function and memory loss later on.

Collaborating with Frazier Healthcare Partners, the team spun out a new company dubbed HilleVax to take Takeda’s norovirus vaccine into Phase 3 trials.

With the Alzheimer’s Association International Conference conference last week, there were plenty of clinical trial news and updates. Here’s a look.

The U.S. FDA is starting off August with a mix of PDUFA dates for acne products, seizure medications and a new manufacturing process for a non-opioid pain killer. Here’s a look.

AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2021.

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Canaccord 41st Annual Growth Conference.

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced new data from its Phase 1 extension study evaluating Trappsol® Cyclo

Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, announced that the Company presented at the 2021 Alzheimer’s Association International Conference (AAIC) in a presentation titled “In vivo validation of therapeutic efficacy of a small molecule lead targeting tau self-association in JNPL3 mice.”

ALK and the pharmaceutical company China Grand Pharmaceutical and Healthcare Holdings Limited (”Grandpharma”) today announced an exclusive licensing agreement that will see ALK’s AAI Jext® registered and launched in China, and will expand ALK’s presence in the country.

Global Cancer Technology today announced that the company has licensed biomarker technology from Baylor Scott & White Research Institute (BSWRI) under an exclusive option to support GCT’s research efforts towards a treatment for glioblastoma.